First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer.
FAZA
FMISO
PET
hypoxia
lung cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Aug 2021
14 Aug 2021
Historique:
received:
25
05
2021
revised:
01
08
2021
accepted:
12
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Hypoxic areas are typically resistant to treatment. However, the fluorine-18-fluoroazomycin-arabinoside (FAZA) and fluorine 18 misonidazole (FMISO) tracers have never been compared in non small cell lung cancer (NSCLC). This study compares the capability of 18F-FAZA PET/CT with that of 18F-FMISO PET/CT for detecting hypoxic tumour regions in early and locally advanced NSCLC patients. We prospectively evaluated patients who underwent preoperative PET scans before surgery for localised NSCLC (i.e., fluorodeoxyglucose (FDG)-PET, FMISO-PET, and FAZA-PET). The PET data of the three tracers were compared with each other and then compared to immunohistochemical analysis (GLUT-1, CAIX, LDH-5, and HIF1-Alpha) after tumour resection. Overall, 19 patients with a mean age of 68.2 ± 8 years were included. There were 18 lesions with significant uptake (i.e., SUVmax >1.4) for the F-MISO and 17 for FAZA. The mean SUVmax was 3 (±1.4) with a mean volume of 25.8 cc (±25.8) for FMISO and 2.2 (±0.7) with a mean volume of 13.06 cc (±13.76) for FAZA. The SUVmax of F-MISO was greater than that of FAZA (
Identifiants
pubmed: 34439254
pii: cancers13164101
doi: 10.3390/cancers13164101
pmc: PMC8392878
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Nucl Med. 2005 Feb;46(2):253-60
pubmed: 15695784
Lung Cancer. 2016 Jan;91:56-66
pubmed: 26711935
Radiother Oncol. 2015 Oct;117(1):106-12
pubmed: 26250803
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1870-8
pubmed: 24781871
J Nucl Med. 2013 Sep;54(9):1543-50
pubmed: 23918733
Curr Radiopharm. 2018;11(1):50-57
pubmed: 29119942
Lung Cancer. 2018 May;119:71-77
pubmed: 29656756
J Nucl Med. 2013 Aug;54(8):1175-80
pubmed: 23753185
Radiother Oncol. 2006 Aug;80(2):151-6
pubmed: 16920211
J Nucl Med. 2006 Dec;47(12):1921-6
pubmed: 17138734
Acta Oncol. 2010 Oct;49(7):934-40
pubmed: 20831480
Biochim Biophys Acta. 2009 Apr;1795(2):162-72
pubmed: 19344680
Clin Transl Imaging. 2017;5(3):225-253
pubmed: 28596947
Cell Metab. 2018 Feb 6;27(2):281-298
pubmed: 29129785
Cancer Sci. 2015 Nov;106(11):1554-60
pubmed: 26292100
J Clin Oncol. 2006 May 1;24(13):2098-104
pubmed: 16648512
Clin Cancer Res. 2013 Jul 1;19(13):3345-52
pubmed: 23633457
Radiother Oncol. 2020 Aug;149:189-196
pubmed: 32417350
Radiother Oncol. 2014 Nov;113(2):198-203
pubmed: 25434768
EJNMMI Res. 2016 Dec;6(1):33
pubmed: 27090118
Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S61-3
pubmed: 17848298
Nucl Med Commun. 2014 Jan;35(1):30-5
pubmed: 24121312
Acta Oncol. 2017 Apr;56(4):516-524
pubmed: 28358668
J Nucl Med. 2017 Jul;58(7):1045-1053
pubmed: 28254869
Oncotarget. 2018 Jan 13;9(11):10005-10015
pubmed: 29515786
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61
pubmed: 27251642
Cancers (Basel). 2020 May 22;12(5):
pubmed: 32455922
Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep;124(3):261-270
pubmed: 28734696
J Biol Chem. 1996 Dec 20;271(51):32529-37
pubmed: 8955077
Q J Nucl Med. 2001 Jun;45(2):183-8
pubmed: 11476169
Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1816-23
pubmed: 21833840
PLoS One. 2016 Jun 20;11(6):e0157606
pubmed: 27322586
Strahlenther Onkol. 2004 Oct;180(10):616-22
pubmed: 15480509
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1383-1392
pubmed: 28315948
Mod Pathol. 1998 Feb;11(2):155-68
pubmed: 9504686
Am J Nucl Med Mol Imaging. 2014 Jun 07;4(4):365-84
pubmed: 24982822
J Clin Oncol. 2007 Sep 10;25(26):4066-74
pubmed: 17827455